Follow
Technical analysis of Kancera
30 September 2020 - 22:14
Technical analysis of the Kancera stock by Long Life Trading....
Please sign in to view full information or sign up for FREE.
What will You get:
An IPOhub original research paper about TOP10 Nordic IPOs in 2020
Fresh Data, updated daily:
- Active and Upcoming Events - IPO’s, New Share Issues, Exercises, Market moves, Upcoming Listings, Acquisitions.
- Live Press releases (news and media).
- Updates on Your favorite prospects to Your email.
For investment decisions:
- Info on 600+ IPOs, 1400+ listings and 5000+ share issue events.
- Access to database with 3000+ growth companies.
- Data which is collected and brought to You from 100+ sources.
Save time and make better investment decisions with IPOhub. Sign up now until it`s FREE!
Kancera AB
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients...
Learn more about company
